

BCR-ABL P190 Quantitation by Real-Time PCR

Clinical Indication and Relevance

- Can confirm the initial diagnosis of p190 *BCR-ABL* positive acute lymphoblastic leukemia (ALL) or chronic myelogenous leukemia (CML).
- Recommended for monitoring minimal residual disease in follow-up samples.

Methodology

RNA is isolated, reverse transcribed and amplified by real-time PCR using specific primers targeting the p190 *BCR-ABL* and *ABL* genes. Quantitative results are obtained by comparing relative levels of p190 *BCR-ABL* and *ABL* transcripts to standard curves. Results are reported as a p190 *BCR-ABL* to *ABL* ratio after calibration with a p190 *BCR-ABL* positive tumor cell line.

Sensitivity

This assay can detect p190 *BCR-ABL* transcripts to a sensitivity of 1 tumor cell in 1000 normal cells.

Turn-around Time

Five to seven working days

Sample Requirements

Collect

- Peripheral blood (PB): 3-5 mL, in purple top (sodium EDTA) tube; yellow top tube (ACD) acceptable.
- Bone marrow (BM): 1-3 mL, drawn into a syringe containing anticoagulant and then delivered in a purple top tube.

Transport

Deliver immediately at 2-8°C (wet ice or cold packs). Do not freeze.

Stability

Ambient - 1 hour; refrigerated – 48 hours.

Note: for RNA based assays, samples should be transported to the laboratory within 8 hours of collection (optimal), or up to a maximum of 48 hours after collection to avoid RNA degradation. RNA integrity is critical, especially for samples used for monitoring minimal residual disease.

Unacceptable Conditions

Serum or plasma; frozen PB or BM; clotted blood; severely hemolyzed samples.

CPT Code(s)

81207: *BCR/ABL1* (t(9;22)) translocation analysis; minor breakpoint, qualitative or quantitative
G0452-26: Molecular pathology procedure; physician interpretation and report

References

1. Beillard E et al. *Leukemia*. 17:2474, 2003
2. Gabert J et al. *Leukemia*. 17:2318, 2003
3. Hughes T et al. *Blood*. 108:28, 2006
4. Hughes T. *Blood Rev*. 20:29, 2006